Skip to main content
S&P 5007,636.94-0.01%DOW51,667.72-0.21%NASDAQ26,462.55+0.17%BTC$81,163.00+6.08%ETH$2,632.67+7.44%GOLD$4,420.70+0.48%OIL$95.52-1.76%
Smart Investors Daily
PB

NASDAQ · PBAXU

Phoenix Biotech Acquisition Corp.

Financial Services · Shell Companies

$10.37

Down-$0.01 (-0.10%)

Updated Sep 18, 2026, 7:38 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
36.54M
P/E ratio
-0.13
Dividend yield
0.00%
52-week range
— – —
Volume
7
Avg. volume
92

Price performance

PBAXU price history

1M range · 0 trading sessions · Daily adjusted prices

PBAXU does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest PBAXU news

The latest Smart Investors Daily articles mentioning PBAXU.

Stock researchCompany · Overview

PBAXU research

Overview

Company profile and research snapshot.

Company profile

Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe. The company was incorporated in 2021 and is based in Oakland, California.

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Nov 22, 2021

Phoenix Biotech Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on November 26, 2021

Oakland, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) (the “Company”), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced that the holders of the Company’s units may elect to separately trade the Class A common shares and warrants underlying the units commencing on November 26, 2021. Those units not separated will continue to trade on the NASDAQ Capital Market under the symbol “PBAXU” and the Class A common shares and warrants are expected to trade under the symbols “PBAX” and “PBAXW”, respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

GlobeNewswire Inc. · Oct 8, 2021

Phoenix Biotech Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment Option

Oakland, CA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) (the “Company”), a blank-check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced the completion of its initial public offering of 17,500,000 units at a price of $10.00 per unit, which includes 2,000,000 units issued pursuant to the exercise of the underwriters’ over-allotment option, for gross proceeds to the Company of $175,000,000. The Company's units began trading on The Nasdaq Global Market (“Nasdaq”) under the symbol "PBAXU" on October 6, 2021. Each unit issued in the offering consists of one share of the Company’s Class A common stock and one-half of one warrant, with each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “PBAX” and “PBAXW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By